louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06755437: Self Treatment with an Electronic Device for Cognitive Rehabilitation in Patients with Subacute Stroke
Official title: Self Treatment with an Electronic Device for Cognitive Rehabilitation in Patients with Subacute Stroke: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Stroke
Cognitive Deficits
Computerized Rehabilitation
Computerized Device
Keywords: stroke
neuropsychological rehabilitation
Lead sponsor: Universita di Verona
Sponsor class: OTHER
First posted: 2025-01-01
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate whether the independent use of an electronic device by a patient with stroke outcomes can enhance the effectiveness of rehabilitative treatment for attentional functions compared to standard treatment.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of ischemic or hemorrhagic stroke;
* Age between 18 and 90 years;
* First stroke event;
* Time since the stroke greater than 30 days;
* Adequate level of comprehension;
* Presence of one or more of the following cognitive disorders: Memory disorders; Attention disorders; Executive function disorders
* Availability of internet access at the patient's home, necessary for telemedicine procedures.

Exclusion Criteria:

* Presence of other neurological conditions;
* Presence of pre-morbid cognitive decline;
* History of psychiatric disorders;
* Alcohol and/or drug abuse;
* Presence of severe uncorrected visual impairments.

Primary outcomes:
measure: Trail Making Test Part A (TMT-A)
timeFrame: From enrollment (within 2 weeks of stroke onset) to the completion of treatment (2 weeks after the start of treatment)
Secondary outcomes:
measure: Trail Making Test Part B (TMT-B)
timeFrame: From enrollment (within 2 weeks of stroke onset) to the completion of treatment (2 weeks after the start of treatment)
measure: Dual task test
timeFrame: From enrollment (within 2 weeks of stroke onset) to the completion of treatment (2 weeks after the start of treatment)
measure: short version of the Elithorn's Perceptual Maze Test
timeFrame: From enrollment (within 2 weeks of stroke onset) to the completion of treatment (2 weeks after the start of treatment)
measure: Stroop Test
timeFrame: From enrollment (within 2 weeks of stroke onset) to the completion of treatment (2 weeks after the start of treatment)
Other outcomes:
Locations:
city: Verona
country: Italy
facility: Azienda Ospedaliera Universitaria Integrata Verona - UOC di Neuroriabilitazione
city: Verona
country: Italy
facility: Azienda Ospedaliera Universitaria Integrata Verona - UOC di Neuroriabilitazione
Study officials:
References:
Clinical trial NCT01846637: Two or Five cm From Pylorus During Laparoscopic Sleeve Gastrectomy
Official title: Comparative Study Between Two and Five cm Resection During Laparoscopic Sleeve Gastrectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Morbid Obesity
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2013-05-03
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators compare two techniques for laparoscopic sleeve gastrectomy. in the first one the distal margin of stapling is 2 cm from the pylorus and in the second it is 6 cm away from the pylorus.


Eligibility criteria: Inclusion Criteria:

* morbid obese patients

Exclusion Criteria:

* contraindication to laparoscopy

Primary outcomes:
measure: percentage of excess weight loss
timeFrame: 2 years
Secondary outcomes:
measure: complications
timeFrame: 2 years
Other outcomes:
measure: improvement of comorbidities
timeFrame: 2 years
Locations:
city: Mansoura
country: Egypt
facility: Gastroenterology Surgical Center
state: Dakahlia
Study officials:
References:
Clinical trial NCT01311037: The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer
Official title: The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer A Prospective Trial
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Advanced Breast Cancer
Keywords: Premenopausal Women with Advanced Breast Cancer
Lead sponsor: King Faisal Specialist Hospital & Research Center
Sponsor class: OTHER
First posted: 2011-03-09
Enrollment: 2
Sex: FEMALE
Minimum age (years): 45
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Receptor Positive Premenopausal Women with Advanced Breast Cancer.

Brief summary: The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women with Advanced Breast Cancer A Prospective Trial.

Detailed description: The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women with Advanced Breast Cancer A Prospective Trial.

Eligibility criteria: Inclusion Criteria:

* Receptor Positive Premenopausal Women with Advanced Breast Cancer.

Exclusion Criteria:

* Any woman other than diagnosis of Receptor Positive Premenopausal with Advanced Breast Cancer.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Riyadh
country: Saudi Arabia
facility: Kfsh & Rc
Study officials:
affiliation: KFSH & RC
name: Al Sayed, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05454137: A Shared Medical Appointment Intervention for Quality of Life Improvement in POTS
Official title: Postural Orthostatic Tachycardia Syndrome: a Pilot, Feasibility Study of an Integrative Shared Medical Appointment Intervention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postural Orthostatic Tachycardia Syndrome
Lead sponsor: University of Arizona
Sponsor class: OTHER
First posted: 2022-07-12
Enrollment: 10
Sex: ALL
Minimum age (years): 21
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Postural orthostatic tachycardia syndrome (POTS) is a clinical syndrome encompassing a myriad of debilitating symptoms that does not have any FDA approved drug therapies. We propose a shared medical appointment intervention where participants will learn lifestyle management therapies and integrative practices that may improve quality of life.


Eligibility criteria: Inclusion Criteria:

* patients with a physician diagnosis of POTS

Exclusion Criteria:

* patients with uncontrolled psychiatric disease
* patients with uncontrolled medical illness including recent myocardial infarction, stroke, and active malignancy
* non-English speakers as the group intervention will be delivered in English
* pregnant women

Primary outcomes:
measure: Recruitment and retention rate
timeFrame: at 4 months
Secondary outcomes:
measure: Change in COMPASS overall score
timeFrame: Baseline and 4 months
measure: Change on Short Form Survey (SF-36) overall score
timeFrame: Baseline and 4 months
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Banner University Medical Center
state: Arizona
Study officials:
affiliation: University of Arizona
name: Talal Moukabary, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02650037: The Air Test: A New Simple, Non-invasive Method to Diagnose Anesthesia-induced Atelectasis
Official title: Estudio de validación de la pulsioximetría Como método diagnóstico no Invasivo de Atelectasia Pulmonar y de la Efectividad de la Maniobra de Capacidad Vital Para la reversión de la Atelectasia Durante el Postoperatorio
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Patients With ASA Status I-III Scheduled for Elective Surgery
Lead sponsor: Fundación para la Investigación del Hospital Clínico de Valencia
Sponsor class: OTHER
First posted: 2016-01-08
Enrollment: 181
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study included all patients with ASA status I-III scheduled for elective surgery.

Brief summary: Anesthesia-induced atelectasis persist in the postoperative period but are not usually diagnosed because imaging techniques are required. The aim of the study is to determine whether the value of SpO2≤96 while breathing room air (0.21 FiO2) for 5 min, maneuver that we defined as the Air Test, was able to diagnose atelectasis in the postoperative period after a general anesthesia.


Eligibility criteria: Inclusion Criteria:

* ASA I-III
* Scheduled for elective surgery

Exclusion Criteria:

* age of \<18 years
* pregnant women
* previous lung resection
* local-regional anesthesia
* cardio-thoracic anesthesia
* preoperative room air SpO2 less than 97%

Primary outcomes:
measure: Presence of postoperative atelectasis meassured by SpO2 levels and confirmed by computed tomography.
timeFrame: 35 minutes post-surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: Department of Anesthesia and Critical Care; Hospital Clinico Universitario
Study officials:
References:
citation: Hemmes SN, Serpa Neto A, Schultz MJ. Intraoperative ventilatory strategies to prevent postoperative pulmonary complications: a meta-analysis. Curr Opin Anaesthesiol. 2013 Apr;26(2):126-33. doi: 10.1097/ACO.0b013e32835e1242.
citation: Magnusson L, Spahn DR. New concepts of atelectasis during general anaesthesia. Br J Anaesth. 2003 Jul;91(1):61-72. doi: 10.1093/bja/aeg085. No abstract available.
citation: Hedenstierna G, Tokics L, Strandberg A, Lundquist H, Brismar B. Correlation of gas exchange impairment to development of atelectasis during anaesthesia and muscle paralysis. Acta Anaesthesiol Scand. 1986 Feb;30(2):183-91. doi: 10.1111/j.1399-6576.1986.tb02393.x.
citation: Ferrando C, Romero C, Tusman G, Suarez-Sipmann F, Canet J, Dosda R, Valls P, Villena A, Serralta F, Jurado A, Carrizo J, Navarro J, Parrilla C, Romero JE, Pozo N, Soro M, Villar J, Belda FJ. The accuracy of postoperative, non-invasive Air-Test to diagnose atelectasis in healthy patients after surgery: a prospective, diagnostic pilot study. BMJ Open. 2017 May 29;7(5):e015560. doi: 10.1136/bmjopen-2016-015560.
Clinical trial NCT00526552: Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes)
Official title: RAPID (Evaluating the Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes in Real World Practice)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dyslipidemia
Diabetes
Keywords: dyslipidemia
rosuvastatin
diabetes
cholesterol
Naturalistic
Observational
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2007-09-10
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Diabetic Mellitus patients with hypercholesteromia in Korean tertiary care centers

Brief summary: To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with diabetes


Eligibility criteria: Inclusion Criteria:

* Hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria

  1. Over 18 years of age
  2. Diagnosed with DM based on fasting or post-load glucose data and/or clinical assessment by the clinician

Exclusion Criteria:

1. Patients already taking other hyperlipidemic agents
2. Patients who do not fulfil the indication criteria for statin therapy
3. Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Research Site
state: Jongro-gu
city: Seoul
country: Korea, Republic of
facility: Research Site
state: Kangnam-gu
city: Seoul
country: Korea, Republic of
facility: Research Site
state: Songpa-gu
Study officials:
affiliation: AstraZeneca Korea
name: Hyunah Caroline Choi
role: STUDY_DIRECTOR
References:
Clinical trial NCT02176252: Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects
Official title: A Phase I, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects in Healthy Male and Female Japanese Subjects After Single and Multiple Doses (Bid) of AZD1722
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteer
Lead sponsor: Ardelyx
Sponsor class: INDUSTRY
Collaborators: name: AstraZeneca
First posted: 2014-06-27
Enrollment: 83
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study is designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy Japanese subjects at increasing doses given for 7 days in order to allow for including Japanese subjects in future global studies. A cohort of Caucasian subjects will be included in the study to evaluate cardiac effects, assessed by digital ECGs (dECG) recordings, also in Caucasian subjects.


Eligibility criteria: Inclusion Criteria:

* Healthy man or woman
* Body mass index between 18 and 29.9 kg/m2, inclusive

Exclusion Criteria:

* Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the gastrointestinal (GI) tract
* Any surgery on the small intestine or colon, excluding appendectomy
* Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, metabolic, endocrine, neurologic, psychiatric disease, or any condition that may interfere with the subject successfully completing the trial or that would present a safety risk to the subject.

Primary outcomes:
measure: Number of patients with adverse events
timeFrame: up to 3 weeks
Secondary outcomes:
measure: pharmacodynamic activity
timeFrame: up to one week
measure: pharmacokinetics
timeFrame: up to one week
Other outcomes:
Locations:
city: Cypress
country: United States
facility: WCCT Global
state: California
Study officials:
affiliation: Ardelyx, Inc.
name: David P Rosenbaum, Ph.D.
role: STUDY_DIRECTOR
References:
citation: Johansson S, Rosenbaum DP, Knutsson M, Leonsson-Zachrisson M. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers. Clin Exp Nephrol. 2017 Jun;21(3):407-416. doi: 10.1007/s10157-016-1302-8. Epub 2016 Jul 1.
Clinical trial NCT02598752: Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
Official title: Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome
Hematological Malignancy
Leukemia
Lymphoma
Myeloma
Keywords: functional performance testing
exercise fitness testing
15-274
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2015-11-06
Enrollment: 11
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Potentially eligible will be identified through and recruited from the Adult Bone Marrow Transplantation clinics at MSK.

Brief summary: The purpose of this study is to see if exercise fitness testing is feasible and safe in persons over 21 years of age who have been diagnosed with a hematological malignancy and are scheduled to undergo a hematopoietic stem cell transplant (HCT). Assessments in this study will look at the capacity of the body before transplantation to see if these measures can help predict how patients do after transplant.


Eligibility criteria: Inclusion Criteria:

* Patients with MSK histologically confirmed hematologic malignancy
* Scheduled for autologous or allogenic HCT at MSKCC
* ≥21 years old
* ECOG performance status of 0 or 1
* Completion of baseline CPET
* Willing to comply with protocol related procedures

Exclusion Criteria:

* Any of the following absolute contraindications to cardiopulmonary exercise testing

  * Acute myocardial Infarction (within 3-5 days of any planned study procedures)
  * Unstable angina
  * Uncontrolled arrhythmia causing symptoms or hemodynamic compromise
  * Recurrent syncope
  * Active endocarditis
  * Acute myocarditis or pericarditis
  * Symptomatic severe aortic stenosis
  * Uncontrolled heart failure
  * Acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures
  * Thrombosis of lower extremities
  * Suspected dissecting aneurysm
  * Uncontrolled asthma
  * Pulmonary edema
  * Respiratory failure
  * Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis)
  * Presence of any other concurrent, actively treated malignancy;
  * History of any other malignancy treated within the past 3 years (other than non-melanoma skin cancer);
  * Room air desaturation at rest ≤85%
  * Mental impairment leading to inability to cooperate

Primary outcomes:
measure: VO2peak
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Jessica Scott, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03113552: Prognostic Impact of the Location of Mitral Valve Prolapse on the Long-term Results of Mitral Plasty
Official title: Prognostic Impact of the Location of Mitral Valve Prolapse on the Long-term Results of Mitral Plasty
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Mitral Valve Prolapse
Mitral Plasty
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2017-04-13
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study of the long-term survival of patients who have had mitral valve prolapse for mitral valve prolapse in Amiens according to the location of the prolapse

Brief summary: Mitral insufficiency (MI) accounts for 24% of adult valvulopathies and affects 7% of subjects older than 75 years. They are the second leading cause of valvulopathy in Europe. The most common etiology is the associated valvular prolapse. Mitral surgery remains the reference treatment for symptomatic MI. The success of this procedure depends on the mitral valve geometry and the location of the prolapse. The site of the prolapse, whether monovalvular, localized to the posterior or anterior leaflet, or bivalvular, influences the possibilities and probably the long-term results of the plasty.


Eligibility criteria: Inclusion Criteria:

* Patients operated between 1988 and 2011
* Presence of a valvular prolapse diagnosed by echocardiography
* Possibility of a complete clinical evaluation at the time of the initial echocardiography

Exclusion Criteria:

* Ischemic MI (including papillary muscle rupture)
* Presence of significant aortic valvulopathy, mitral valvular stenosis or congenital disease
* History of cardiac surgery

Primary outcomes:
measure: Survival defines as the time between the date of surgery and the death or date of the last news
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens Picardie
state: Picardie
Study officials:
References:
Clinical trial NCT05187052: Rigid Telescopes, C-MAC, Flexible Bronchoscopy for Intubation in Patients With Anticipated Difficult Airways
Official title: Rigid Telescopes, C-MAC, Flexible Bronchoscopy for Intubation in Patients With Anticipated Difficult Airways
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Videolaryngoscopy
Keywords: Airway management, Difficult airway, Tracheal intubation
Lead sponsor: Yuzuncu Yıl University
Sponsor class: OTHER
First posted: 2022-01-11
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Difficult airway management in phonomicrosurgery requiring endotracheal tube (ETT) between 18-90 years old patients.

Brief summary: The primary outcome of the study is the first-attempt orotracheal intubation success rate and the secondary outcomes include intubation time, mucosal injury, and complications during intubation.

Detailed description: Difficult airway management in phonomicrosurgery requiring endotracheal tube (ETT) placement is highly important for both the anesthetist and the surgeon. The use of rigid telescopes in the intubation of children with difficult intubation, such as those with Pierre Robin sequence (PRS), has been previously described in the literature. In addition, the use of Airtraq™ and rigid endoscopes in patients undergoing phonomicrosurgery, particularly in patients with difficult laryngoscopy, has also been reported in the literature. However, the uses of these techniques have mostly been described in the administration of surgery or in defining airway disease. In this study, we aimed to evaluate the use of rigid telescopes during intubation, particularly in patients with a difficult airway, and to compare them with videolaryngoscope Macintosh (V-MAC) and flexible fiberoptic bronchoscope.

Eligibility criteria: Inclusion Criteria:

Patients with a modified Cormack-Lehane (C-L) grade of 3 and 4, Wilson score of ≥ 6, Thyromental distance (TMD) distance of ≤ 6 cm, Sternomental distance (SMD) ≤ 13.

Exclusion Criteria:

Patients that had severe mouth opening (\<2.5 cm), Required nasotracheal intubation, Upper airway and pharyngeal diseases, Presence of cervical spine anomalies, Emergency procedures, Failed mask ventilation, ASA III and IV score, Patients who were allergic to any of the drugs to be used during premedication and anesthesia.

Primary outcomes:
measure: Comparison of three video laryngoscopes: Rigid telescopes, C-MAC, flexible bronchoscopy for intubation in patients with anticipated difficult airways
timeFrame: 1 day
measure: Comparison of three video laryngoscopes: Rigid telescopes, C-MAC, flexible
timeFrame: 1 day
Secondary outcomes:
measure: Comparison of three video laryngoscopes: Rigid telescopes, C-MAC, flexible
timeFrame: 1 day
Other outcomes:
Locations:
city: Van
country: Turkey
facility: Yaser Said Cetin
Study officials:
References: